A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants with Aggressive and Indolent B-cell Malignancies
-(Cohort D): To evaluate the safety and tolerability of zilovertamab vedotin -(Cohort C): To evaluate the safety and tolerability of zilovertamab vedotin in combination with nemtabrutinib -To evaluate zilovertamab vedotin with respect to objective response rate: Cohorts A, B, D (FL), and E: per Lugano, Response Criteria as assessed by BICR, Cohorts D (CLL) and F: per iwCLL, Criteria as assessed by investigate -To evaluate zilovertamab vedotin in combination with nemtabrutinib with respect to objective response rate: Cohort C: per Lugano Response Criteria as assessed by investigator
Adult
Treatment
CTRC Inpatient
University of Colorado Hospital
Steven Bair, MD
Protocol Number: 22-1252
More information available at ClinicalTrials.gov: NCT05458297
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers